Physician profile
Alexander Michael Abud
NPI 1235669706
$112,769.52
in general payments reported to CMS, 2019-2025
24 companies · $9,743 in 2025
The $9,743 reported for 2025 was more than what 89% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $108 · 2021: $90K · 2022: $190 · 2023: $941 · 2024: $12K · 2025: $9,743.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $15K · Food and Beverage: $3,672 · Travel and Lodging: $2,725 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $550.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $15,493.00 |
| Food and Beverage | $3,672.10 |
| Travel and Lodging | $2,725.48 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $550.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $90,525.72 | 2021-2025 | Tysabri, Vumerity, Tysabri |
| Emd Serono, INC. | $9,185.09 | 2023-2025 | Mavenclad, Mavenclad |
| Argenx US, INC. | $5,513.08 | 2024-2025 | Vyvgart Hytrulo |
| Tg Therapeutics, INC. | $1,837.28 | 2023-2025 | |
| Genentech USA, INC. | $1,642.24 | 2020-2025 | Ocrevus, Enspryng |
| Lundbeck LLC | $1,306.61 | 2023-2025 | Vyepti |
| Genentech, INC. | $623.37 | 2021-2025 | Ocrevus, Enspryng |
| Amgen INC. | $605.88 | 2024-2025 | Uplizna |
| Novartis Pharmaceuticals Corporation | $347.93 | 2023-2025 | |
| Celgene Corporation | $323.91 | 2022-2025 | Zeposia |
| Pfizer INC. | $238.56 | 2023-2024 | |
| Alexion Pharmaceuticals, INC. | $119.74 | 2024-2025 | Ultomiris |
| Sandoz INC. | $83.12 | 2024 | |
| Acadia Pharmaceuticals INC | $81.86 | 2023-2024 | Nuplazid, Daybue |
| Teva Pharmaceuticals USA, INC. | $78.30 | 2023-2025 | Austedo Xr, Austedo Xr |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $53.43 | 2023-2024 | Botox |
| Neurocrine Biosciences, INC. | $50.52 | 2023-2024 | Ingrezza, Ongentys |
| Ge Healthcare | $27.09 | 2023 | |
| Alnylam Pharmaceuticals INC. | $25.52 | 2024 | Onpattro |
| Ani Pharmaceuticals, INC. | $23.28 | 2024 | Purified Cortrophin Gel |
| Ucb, INC. | $22.65 | 2024 | Zilbrysq |
| Jazz Pharmaceuticals INC. | $18.58 | 2024 | |
| Genzyme Corporation | $18.24 | 2024 | |
| Baxter Healthcare | $17.52 | 2023 | Hillrom - Volara System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexander Abud listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.